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ERK phosphorylation and transcription factor activation wereCerivastatin prevents angiotensin II-induced renal injury inde-
reduced. In addition, in vitro incubation of vascular smoothpendent of blood pressure- and cholesterol-lowering effects.
muscle cells with cerivastatin (0.5 mmol/L) almost completelyBackground. Statins are effective in prevention of end-
prevented the Ang II-induced ERK phosphorylation.organ damage; however, the benefits cannot be fully explained
Conclusion. Cerivastatin reduced inflammation, cell prolif-on the basis of cholesterol reduction. We used an angiotensin
II (Ang II)-dependent model to test the hypothesis that ceriva- eration, and iNOS induction, which led to a reduction in cellular
statin prevents leukocyte adhesion and infiltration, induction damage. Our findings suggest that 3-hydroxy-3-methylglutaryl
of inducible nitric oxide synthase (iNOS), and ameliorates end- coenzyme (HMG-CoA) reductase inhibition ameliorates Ang
organ damage. II-induced end-organ damage. We suggest that these effects
Methods. We analyzed intracellular targets, such as mitogen- were independent of cholesterol.
activated protein kinase and transcription factor (nuclear
factor-kB and activator protein-1) activation. We used immu-
nohistochemistry, immunocytochemistry, electrophoretic mo-
3-Hydroxy-3-methylglutaryl coenzyme (HMG-CoA)bility shift assays, and enzyme-linked immunosorbent assay
techniques. We treated rats transgenic for human renin and reductase inhibitors (statins) ameliorate glomerular in-
angiotensinogen (dTGR) chronically from week 4 to 7 with jury and preserve renal function in several models, in-
cerivastatin (0.5 mg/kg by gavage). cluding 5/6 nephrectomy and the diabetic nephropathy
Results. Untreated dTGR developed hypertension, cardiac
of Zucker rats [1–4]. The drugs are also effective in ahypertrophy, and renal damage, with a 100-fold increased albu-
model of the nephrotic syndrome [5]. Since lipid distur-minuria and focal cortical necrosis. dTGR mortality at the
age of seven weeks was 45%. Immunohistochemistry showed bances are not a salient feature in most rat models of
increased iNOS expression in the endothelium and media of disease, the beneficial effects of statins may involve
small vessels, infiltrating cells, afferent arterioles, and glomeruli mechanisms independent of their cholesterol-loweringof dTGR, which was greater in cortex than medulla. Phosphor-
effect [6, 7]. In human disease, alternative modes ofylated extracellular signal regulated kinase (p-ERK) was in-
action have also been postulated. Support for cellularcreased in dTGR; nuclear factor-kB and activator protein-1
were both activated. Cerivastatin decreased systolic blood pres- mechanisms has accrued involving effects on chemo-
sure compared with untreated dTGR (147 6 14 vs. 201 6 6 kines, surface adhesion molecules, endothelin expres-
mm Hg, P , 0.001). Albuminuria was reduced by 60% (P 5 sion, and nitric oxide synthase (NOS) activity [8–13].0.001), and creatinine was lowered (0.45 6 0.01 vs. 0.68 6 0.05
Data from several laboratories have shown that statinsmg/dL, P 5 0.003); however, cholesterol was not reduced.
can directly interfere with intracellular signaling path-Intercellular adhesion molecule-1 and vascular cell adhesion
molecule-1 expression was diminished, while neutrophil and ways. Statins inhibit the activation of the transcription
monocyte infiltration in the kidney was markedly reduced. factor nuclear factor-kB (NF-kB) in vitro [14]. The exact
mechanisms whereby statins exert these intracellular ef-
fects are not yet clear; however, the geranolgeranyl path-Key words: statins, inducible nitric oxide synthase, MAP kinase, nu-
clear factor-kB, cell adhesion. way may be involved. Statins interfere with farnesylation
by farnesol depletion and could thereby modify the acti-
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cellular mechanisms of renal damage via the ras-depen- R&D Systems, Abingdon, UK), neutrophils (HIS48; Phar-
Mingen, Heidelburg, Germany), the Ki-67, a nuclear celldent signaling pathway and thereby reduce the activity of
downstream signaling components such as raf, mitogen- proliferation-associated antigen expressed in all active
stages of the cell cycle (MIB-5; Dianova, Hamburg, Ger-activated protein (MAP) kinases, and the transcription
factors NF-kB and activator protein-1 (AP-1) [16–19]. many), and polyclonal inducible NOS (iNOS) and endo-
thelial NOS (ABR, Golden, CO, USA), phosphorylatedTo test this hypothesis, we used an angiotensin II (Ang
II)-dependent transgenic rat model. The rats carry both extracellular signal regulated kinase (p-ERK; Santa Cruz,
Heidelberg, Germany). After washing with TBS, the sec-human renin and angiotensinogen genes, develop hyper-
tension, and die of renal and cardiac damage by the tions were incubated with a bridging antibody (rabbit-
anti-mouse IgG; Dako, Hamburg, Germany) for 30 min-age seven to eight weeks. The tissue damage features
inflammation, microthrombosis, fibrinoid necrosis, fi- utes at room temperature and washed again with TBS.
The APAAP-complex (Dako) was applied, and the sec-brosis, and matrix production [20]. We have shown that
NF-kB and AP-1 activation, chemokine production, ad- tions were incubated for 30 minutes at room tempera-
ture. The immunoreactivity was visualized by develop-hesion molecule expression, plasminogen activator-1,
and tissue factor expression are prominent features in ment in a mixture of naphthol-AS-BI-phosphate (Sigma)
with neufuchsin (Merck, Darmstadt, Germany). Endog-this model [21, 22].
enous alkaline phosphatase was blocked by addition of
10 mmol/L levamisole (Sigma) to the substrate solution.
METHODS
The sections were slightly counterstained in Mayer’s he-
Study design malaun (Merck) blued in a tap water and mounted with
GelTol (Coulter-Immunotech, Hamburg, Germany). Prep-Experiments were conducted in four-week-old male
dTGR and age-matched Sprague-Dawley (SD) rats. The arations were examined under a Zeiss Axioplan-2 micro-
scope (Zeiss, Jena, Germany) and photographed usingdTGR line and characteristics are described elsewhere
[21, 22]. The rats were purchased from RCC Ltd. (Fu¨l- a color reversal film Agfa CTX 100. Microscopy with
phase contrast resolution was used to show the localiza-linsdorf, CH), kept in rooms at 24 6 28C, fed a standard
rat diet containing 0.2% sodium by weight, and allowed tion of p65 in the kidney (Fig. 3). Semiquantitative scor-
ing of ED-1–positive cells in the kidney was performedfree access to tap water. All procedures were done ac-
cording to guidelines from the American Physiological using computerized cell count program (KS 300 3.0;
Zeiss). Fifteen different areas of each heart and kidneySociety and were approved by local authorities. The
statin dTGR group (N 5 15) received cerivastatin for samples (N 5 5 in all groups) were analyzed. The samples
were examined without knowledge of the rats’ identity.three weeks by gavage once a day (0.5 mg/kg). Control
dTGR (N 5 20) and SD rats (N 5 15) received vehicle
Electrophoretic mobility shift assay(1% sodium carboxymethylcellulose).
Systolic blood pressure was measured weekly by the Tissue extracts and EMSA for the transcription factor
NF-kB were performed as described earlier [25]. Briefly,tail-cuff method under light ether anesthesia 20 hours
after the last drug dose. Urine samples were collected frozen total kidneys were pulverized in liquid nitrogen
with a pestle and mortar and were resuspended in 3 mLover a 24-hour period. Rats were killed at the age of
seven weeks. The kidneys and hearts were washed with 50 mmol/L Tris (pH 7.4) containing a complete inhibitor
tablet (Roche Boehringer) and 1 mmol/L Na-ortho-van-ice-cold saline, blotted dry, and weighed. For electropho-
retic mobility shift assay (EMSA) of NF-kB and AP-1, adate (Sigma Chemie, Deisenhofen, Germany). The sus-
pension was centrifuged (4000 3 g, 4 min, 48C). Thethe tissues were snap frozen in liquid nitrogen for immu-
nohistochemistry in isopentane (2358C) and were stored pellet was resuspended and lyzed for 30 minutes in whole
cell lysate buffer [20 mmol/L HEPES, pH 7.9, 350 mmol/Lat 2808C.
NaCl, 20% glycerol, 1 mmol/L MgCl2, 0.5 mmol/L ethyl-
Immunohistochemistry enediaminetetraacetic acid (EDTA), 0.1 mmol/L egtazic
acid (EGTA), and 1% NP-40] and again centrifugedFrozen kidneys and hearts were cryosectioned at 6 mm
thickness and were air dried as described earlier [23–25]. (13,000 3 g, 10 min, 48C). The supernatant was aliquoted
and frozen in liquid nitrogen and stored at 2808C untilThe sections were fixed with cold acetone and were air
dried and washed with Tris-buffered saline (TBS; 0.05 use. The protein concentration for EMSA and Western
blot was quantitated by the Bradford method. Formol/L Tris buffer, 0.15 mol/L NaCl, pH 7.6). The sections
were incubated for 60 minutes in a humid chamber at room EMSA, total kidney homogenates (50 mg) were incu-
bated in a binding reaction medium [2 mg poly dI-dC, 1temperature with primary monoclonal antibodies against
rat monocytes/macrophages (ED1; Serotec, Oxford, UK), mg bovine serum albumin (BSA), 1 mmol/L dithiothrei-
tol (DTT), 20 mmol/L HEPES, pH 8.4, 60 mmol/L KCl,NF-kB subunit p65 (Roche Boehringer, Mannheim, Ger-
many), intercellular adhesion molecule-1 (ICAM-1; 1A29; and 8% Ficoll] with 0.5 ng of 32P-dATP end-labeled
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oligonucleotide, containing the NF-kB binding site from before the end of the study (P , 0.05). Small vessels
showed increased intimal and medial thickness as wellthe multiple histocompatibility complex (MHC)-enhancer
(H2K, 59-GATCCAGGGCTGGGGATTCCCCATCTC as hyaline deposits. The renal tubules were frequently
swollen and filled with proteinaceous material (Fig. 1A).CACAGG) at 308C for 30 minutes. For AP-1 double-
stranded oligonucleotides containing the consensus se- Chronic treatment with cerivastatin prevented vascular
injury in small renal vessels and extracellular matrix for-quence for AP-1 (59-GATCGAACTGACCGCCCGCC
GCCCGT-39; Santa Cruz Biotechnologies, Santa Cruz, mation (Fig. 1B).
CA, USA) were radiolabeled with g-32P with the use
Effect of cerivastatin on blood pressureof T4 polynucleotide kinase by standard methods and
purified over a column. The DNA-protein complexes Systolic blood pressure of cerivastatin-treated rats was
significantly decreased (54 mm Hg) compared with un-were analyzed on a 5% polyacrylamide gel 0.5% Tris
buffer and were dried and autoradiographed. In competi- treated dTGR (147 6 14 vs. 201 6 6 mm Hg, P , 0.001;
Fig. 2). dTGR showed a progressive increase in systoliction assays, 50 or 100 ng unlabeled H2K oligonucleotides
were used. blood pressure from five to seven weeks. After two weeks
of treatment, cerivastatin prevented the increase in sys-
Immunocytochemistry tolic blood pressure seen in dTGR. However, the blood
pressure of cerivastatin-treated rats was significantly ele-Rat aortic vascular smooth muscle cells (VSMCs) were
obtained as described earlier. VSMCs were incubated vated compared with nontransgenic SD rats (147 6 14
vs. 109 6 2 mm Hg, P , 0.001, N 5 10 to 17; Fig. 2).with cerivastatin (5 mmol/L) or buffer for 20 minutes.
Cells were then exposed to Ang II (1027 mol/L), and
Effect of cerivastatin on relative kidney weight,ERK phosphorylation was assessed after one minute
albuminuria, creatinine, and ureausing confocal microscopy. Immediately after the experi-
There was a progressive increase in 24-hour albumin-ments, the cells were fixed with 4% paraformaldehyde
uria in untreated dTGR from five to seven weeks. Ceri-and were permeabilized with 80% methanol at 2208C
vastatin ameliorated but did not eliminate the develop-and stained with a commercially available antibodies
ment of albuminuria in dTGR (6.1 6 2.5 vs. 17.5 6 2.3directed against p-ERK (Santa Cruz). Cells were then
vs. 0.3 6 0.1 mg/day for week 7, P , 0.001, N 5 7 toexposed to the secondary antibody FITC-conjugated
17; Fig. 3A). Plasma creatinine (0.45 6 0.01 vs. 0.68 6antirabbit, at 1:100, 1% bovine serum albumin/phos-
0.05 vs. 0.49 6 0.01 mg/dL, P , 0.01, N 5 8 each; Fig.phate-buffered saline; Dianova) for 60 minutes. The
3B) and plasma urea (49 6 4 vs. 90 6 22 vs. 45 6 2preparation was mounted with 50% glycerol under a
mg/mL, P , 0.05, N 5 8 each; Fig. 3C) were significantlyglass cover slip on a Nikon-Diaphot (Tokyo, Japan) mi-
lower in cerivastatin-treated compared with untreatedcroscope. A Biorad MRC 600 confocal imaging system
dTGR and were similar to SD rat levels. Plasma choles-(Biorad Laboratories, Munich, Germany) with an argon/
terol levels in untreated dTGR were 2.84 6 0.2 mmol/L.krypton laser was used. At least 10 to 18 cells from
However, nontransgenic rats tended to have lower levelseach of three experiments were examined under each
(2.3 6 0.1 mmol/L at week 7, P 5 0.07, N 5 7). Treatmentexperimental condition. The results were reproduced by
with cerivastatin did not significantly influence plasmatwo separate investigators, and multiple experiments
cholesterol compared with dTGR and SD rats (2.5 6were done. The observers were unaware of the experi-
0.1 mmol/L at week 7, P 5 0.3 and P 5 0.7, respectively,mental design and antibodies used.
N 5 8 each; Fig. 3D). Relative kidney weight was signifi-
Statistical analysis cantly higher in dTGR than in cerivastatin-treated rats
and SD rats (4.8 6 0.1 vs. 4.3 6 0.1 vs. 3.7 6 0.1 mg/gData are presented as means 6 SEM. Statistically
body weight at week 7, P , 0.01, N 5 10 to 15). Bodysignificant differences in mean values were tested by
weight of the rats were not different between dTGR andanalysis of variance and Scheffe´ test. A value of P , 0.05
cerivastatin-treated rats (217 6 6 vs. 232 6 8 g at weekwas considered statistically significant. The data were
7, P 5 0.3, N 5 10 to 15). However, SD rats (264 6analyzed using Statview.
8 g) were slightly heavier compared with dTGR and
cerivastatin-treated dTGR (P , 0.05 N 5 10 to 15).
RESULTS
Cerivastatin reduced leukocyte infiltration andRenal histology and mortality dTGR developed hy-
adhesion molecule expressionpertension, severe renal damage, and cardiac hypertro-
phy with focal necrosis. Nine of 20 untreated dTGR First, we analyzed the effects of cerivastatin on neutro-
(45%) died before the end of the study at seven weeks. phils and monocytes in our model. There was significant
Cerivastatin showed a markedly reduced mortality (3 of leukocyte infiltration in renal tissue of dTGR. Neutro-
phils (Fig. 4A, upper panels) were mostly present within15; 20%), while none of the nontransgenic SD rats died
Fig. 1. Periodic acid-Schiff–stained section
from a rat transgenic for human renin and angi-
otensinogen (A; dTGR) and cerivastatin-treated
(B) kidneys. Small vessels showed increased
intimal and medial thickness, as well as hyaline
deposits; tubules were frequently swollen and
filled with proteinaceous material. Chronic
treatment with cerivastatin prevented vascu-
lar injury and extracellular matrix formation.
Fig. 4. Representative immunohistochemical photomicrographs of the infiltration of neutrophils (A–C ) and ED-1–positive monocytic cells (D–F )
in the kidneys of dTGR, dTGR treated with cerivastatin, and SD rats. Neutrophils predominantly infiltrated in the glomeruli, while ED-1–positive
cells showed mainly perivascular and peritubular infiltration in untreated dTGR kidneys. Cerivastatin prevented the cellular infiltration of both
neutrophils and monocytes/macrophages almost completely. Neutrophils and ED-1–positive monocytic cells are stained in red.
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Effect of cerivastatin on iNOS expression
Next, we investigated the effects of cerivastatin on
iNOS expression. These results are shown in Figure 7.
We observed a strong increase in iNOS expression in
the glomeruli (upper panels) and in the vessel wall of
renal arterioles (lower panels compared with SD con-
trols). Treatment with cerivastatin greatly reduced the
iNOS immunoreactivity both in the blood vessels and
the glomeruli. In contrast to iNOS, endothelial NOS was
markedly increased in dTGR and cerivastatin-treated
rats compared with SD rats.
Effect of cerivastatin on cell proliferation
In untreated dTGR, the number of Ki-67–positive cells
in the kidney was significantly higher than that of SD
rats. Cell proliferation was more dominant in the medulla
of dTGR compared with cortex. Nevertheless, ceriva-
Fig. 2. Systolic blood pressure in dTGR (d), dTGR treated with ceri-
statin reduced vascular cell proliferation in both cortexvastatin (m), and Sprague-Dawley (SD; h) rats. Systolic blood pressure
of dTGR increased from weeks 5 to 7. Systolic blood pressure of cerivas- and medulla (data not shown).
tatin-treated rats showed a lower blood pressure compared with un-
treated dTGR, but significantly higher compared to nontransgenic con- Effect of cerivastatin on p-ERK, AP-1, and Nuclear
trols. Results are expressed as mean 6 SEM of 10 to 17 animals per
factor-kB activationgroup. *P , 0.01 dTGR vs. cerivastatin-treated; #P , 0.01 cerivastatin-
treated vs. SD. The possible intracellular mechanisms of the observed
protective effects of cerivastatin were then analyzed. We
first analyzed the activation of MAP kinase by using spe-
cific antibodies which only detect the phosphorylated, ac-the glomerulus and, to a lesser extent, in perivascular areas.
tive form of extracellular signal regulated kinase (p-ERK).In contrast, monocytes/macrophages were mostly local-
In untreated transgenic rats, an increase in phosphoryl-ized in the perivascular space and between the tubules
ated ERK in the vessel wall, glomeruli, and the peritubu-(Fig. 4D, lower panels). Treatment with cerivastatin pre-
lar space was observed (Fig. 8). An even more pronouncedvented neutrophil infiltration almost completely. Ceri-
increase was also present in the medulla (data not shown).vastatin also had an inhibitory effect on monocyte infil-
Treatment with cerivastatin decreased, but did not abol-tration. Semiquantitative cell count analysis confirmed
ished this staining pattern in the cortex and in the medulla.the significant reduction of monocyte/macrophage infil-
We next investigated the activation of the transcrip-tration in the kidney after cerivastatin treatment (P ,
tion factors NF-kB and AP-1, which are important regu-0.001; Fig. 5).
lators of ICAM-1 and iNOS gene expression. EMSAWe then investigated the effect of cerivastatin on the
was used for the detection of NF-kB and AP-1 DNAexpression of adhesion molecules. The expression of
binding activity in the kidney. Both NF-kB (Fig. 9A)ICAM-1 in the kidney (Fig. 6A) was increased in the
and AP-1 (Fig. 9B) showed a greatly increased activityintima, adventitia, and the perivascular space of the small
in the kidneys of dTGR compared with SD rats. Ceriva-vessels in untreated dTGR. Glomeruli and tubules showed
statin treatment reduced renal DNA binding activity ofincreased ICAM-1 expression. Expression of ICAM-1 was
NF-kB and AP-1 almost completely. An immunohisto-markedly reduced by treatment with cerivastatin and
chemical analysis of the subunit p65 of NF-kB in the kid-was similar compared with the constitutive ICAM-1 ex-
ney was also performed. The expression of p65 was in-pression in control animals at week 7. The expression
creased in the endothelium, smooth muscles cells of smallof vascular cell adhesion molecule-1 (VCAM-1) in un-
vessels, infiltrated cells, glomeruli, and tubules of dTGR.treated dTGR was mostly observed in the intima of arte-
Cerivastatin reduced p65 expression (data not shown).rioles. As in the case of ICAM-1, treatment with cerivas-
tatin reduced the up-regulation of VCAM-1, and no
Effect of cerivastatin on Ang II-induced ERKdifference between treated animals and SD control ani-
phosphorylation in vitromals could be observed (data not shown). These results
To verify with certainty that cerivastatin indeed inter-demonstrate that treatment with cerivastatin reduced
feres with Ang II-induced ERK phosphorylation, in vitrothe infiltration of both neutrophils and monocytes and
experiments were performed. Ang II-induced ERKsimultaneously inhibited the increased expression of ad-
hesion molecules. phosphorylation was analyzed with and without prior
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Fig. 3. (A) Twenty-four–hour urinary albumin excre-
tion in dTGR, dTGR treated with cerivastatin, and SD
rats. dTGR showed 100-fold increased albuminuria,
which was reduced by 60% after cerivastatin treatment.
Plasma creatinine (B) and plasma urea (C) levels were
increased in dTGR, while the plasma levels were not
elevated after cerivastatin treatment. Plasma cholesterol
levels in untreated dTGR tended to higher levels (P 5
0.07). Treatment with cerivastatin did not significantly
influence plasma cholesterol compared with dTGR and
SD rats (P 5 0.3 and P 5 0.7, respectively, D). Results
are expressed as mean 6 SEM of 8 to 17 animals per
group (*P , 0.05).
tion with cerivastatin (N 5 3, P , 0.01). The inhibitory
effect was also observed after longer cerivastatin incuba-
tion times (6, 12, and 24 hours).
DISCUSSION
We tested the hypothesis that in a lipid-independent
transgenic animal model of Ang II-mediated organ dam-
age, HMG-CoA reductase inhibition ameliorates renal
failure and inhibits inflammatory changes such as adhe-
sion molecule expression, cell infiltration, and iNOS ex-
pression. In addition, we investigated whether specific
intracellular signaling pathways are influenced by ceri-
vastatin. We showed that cerivastatin reduced MAP ki-
nase activation, inhibited AP-1 and NF-kB binding activ-
ity, prevented inflammatory responses, and ameliorated
renal damage. We selected a dose that was considered suf-
ficiently high to lower total cholesterol in rats; however,Fig. 5. Semiquantitative scoring of ED-1–positive monocytic cells in
the kidney was performed using a computerized cell-count program. even this relatively high dose, compared with human
Fifteen different areas of each kidney were analyzed. Results are ex- treatment, did not lower total cholesterol significantly.
pressed as mean 6 SEM of five animals per group (*P , 0.001).
Our animal model features hypertension, albuminuria,
severe inflammatory changes, cardiac hypertrophy, and
focal necrosis in heart and kidney. Untreated dTGR
VSMC incubation with cerivastatin. VSMCs were incu- have a 50% mortality at seven weeks [20, 22]. Earlier
bated with cerivastatin (5 mmol/L) or buffer for 20 min- we showed that Ang II production in the kidneys and
utes. Cells were then exposed to Ang II (1027 mol/L), elsewhere is responsible for this severe vasculopathy
and ERK phosphorylation was assessed after one minute [21]. Our findings suggest that cerivastatin influences the
using confocal microscopy. The results of these experi- Ang II-induced cellular mechanisms directly, indepen-
ments are shown in Figure 10. Ang II induced a rapid dent of changes in cholesterol.
increase in p-ERK immunoreactivity within one minute. Cerivastatin led to a decrease in blood pressure com-
pared with nontreated animals. The blood pressure-low-This response was almost abolished by the prior incuba-
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Fig. 6. Representative immunohistochemical photomicrographs of intercellular adhesion molecule-1 (ICAM-1) in the kidney of dTGR (A),
cerivastatin-treated dTGR (B), and SD rats (C ). The expression of ICAM-1 was increased in the intima, adventitia, and the perivascular space
of the small dTGR vessels. Glomeruli and tubuli showed frequently increased ICAM-1 expression. Stimulation of ICAM-1 was markedly reduced
by cerivastatin.
Fig. 7. Representative immunohistochemical photomicrographs of inducible nitric oxide synthase (iNOS) of kidneys from dTGR, cerivastatin-
treated, and SD rats. iNOS expression was increased in glomeruli and the vessel wall of dTGR. Cerivastatin reduced the iNOS expression.
ering effect of statin treatment may be due to the preven- inhibitors was reported [26]. A blood pressure-lowering
effect of statins was also observed in animal models oftion of renal injury. However, we cannot rule out a direct
effect of statins on blood pressure. Recently, a reduction hypertension. These results have recently been verified
in a double-blind, crossover trial in humans [27]. The effectin blood pressure treatment by statins in hypercholes-
terolemic patients using angiotensin-converting enzyme may be due to the inhibition of isoprenoid synthesis, which
Park et al: Cerivastatin in Ang II-induced end-organ damage 1427
Fig. 8. Representative immunohistochemical photomicrographs of phosphorylated extracellular signal regulated kinase (p-ERK) in the kidney of
dTGR (A), cerivastatin-treated dTGR (B), and SD rats (C ). The expression of p-ERK was increased in the vessel wall, glomeruli, and interstitium
of dTGR. Expression of p-ERK was markedly reduced by cerivastatin.
Fig. 10. Effects of cerivastatin on the angiotensin (Ang) II-induced phosphorylated extracellular signal regulated kinase (p-ERK) in vascular
smooth muscle cells (VSMCs). Confocal micrographs demonstrate an increase in p-ERK immunoreactivity after exposure Ang II (1027 mol/L) for
one minute. Prior exposure of the VSMCs by cerivastatin (5 mmol/L) almost abolished the Ang II-induced p-ERK (N 5 3, P , 0.05).
subsequently influences VSMC signaling [28]. The cerivas- infiltration was almost abolished. Neutrophils are impor-
tant mediators of injury in acute inflammatory renal dis-tatin-mediated decrease in blood pressure may have con-
tributed to the renoprotective effect. However, we do not eases [30]. Cerivastatin also inhibited the expression of
the endothelial cell adhesion molecule ICAM-1. Sincebelieve that a blood pressure-lowering action of ceriva-
statin had a major effect, since effective antihypertensive ICAM-1 is responsible for neutrophil adhesion to the
endothelium and subsequent infiltration [30], cerivasta-triple treatment (hydralazine, reserpine, and hydrochloro-
thiazide) in our model only partially prevented tissue dam- tin probably inhibited neutrophil infiltration via inhibi-
tion of ICAM-1. This assumption is supported by earlierage and did not reduce inflammation [29].
Cerivastatin treatment inhibited the inflammatory findings from Guijarro et al, showing that statins inhibit
the ICAM-1 expression in mesangial cells in vitro [31].process in our animal model considerably. Neutrophil
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Fig. 9. Effects of cerivastatin on the activa-
tion of DNA binding nuclear factors in the
kidney. Electrophoretic mobility shift assay
(EMSA) for the detection of nuclear factor-kB
(NF-kB; A) and activated protein-1 (AP-1; B)
shows a higher DNA binding activity of dTGR
kidney homogenates compared with SD rats.
Cerivastatin treatment reduced levels of both
NF-kB and AP-1 DNA binding activity. Each
lane represents a single rat kidney homoge-
nate. Specific DNA binding of NF-kB and
AP-1 is indicated by the arrow. EMSA was
performed three times independently with
similar results.
We recently showed that down-regulation of ICAM-1 and growth factors released from these monocytes are
also affected by statins. Since monocytes and their prod-prevents acute renal failure and reperfusion injury in rat
kidney [32]. ucts play an important role in the pathogenesis of acute
and chronic atherosclerotic syndromes, the beneficial ef-Monocyte infiltration and the expression of the adhe-
sion molecule VCAM-1 were reduced by cerivastatin fects of statins seen in patients with chronic vascular
disease may be related in part to their effect on monocytetreatment. Several reports have demonstrated the partic-
ipation of monocyte/macrophages in the onset and pro- infiltration.
Cerivastatin greatly reduced iNOS expression in thegression of various renal diseases [33]. Since monocytes
play a role in long-term pathological changes and chronic dTGR. NO regulates numerous physiological processes,
including smooth muscle contractility, platelet reactivity,renal failure and have been associated with matrix accu-
mulation and fibrosis [34], our findings suggest that ceri- and the cytotoxic activity of leukocytes. Because of the
ubiquitous nature of NO, inappropriate release of thisvastatin has a direct influence on these processes. Statins
improve long-term outcome in renal transplantation mediator has been linked to the pathogenesis of a num-
ber of disease states [37]. While NO serves beneficial[35, 36], and the positive effect of statins on chronic
vascular changes in the kidney may be partially due to roles as a messenger and host defense molecule, exces-
sive NO production can be cytotoxic. The result of NO’stheir direct effects upon monocyte/neutrophil infiltra-
tion. We are presently investigating whether cytokines reaction with reactive oxygen and nitrogen species leads
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